Patients with tumors lacking IDH mutations, such as astrocytoma, IDH wild type (IDHwt) (WHO grade 2 or 3), and glioblastoma, IDHwt (WHO grade 4), are known to have a poorer prognosis than their IDH mutant counterparts [1,3]. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).